

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

NCT06528691

Status	RECRUITING
Phase	Phase 2
Sponsor	St. Jude Children's Research Hospital
Enrollment	52 participants

Key Eligibility Criteria

Inclusion (44)

- Age from birth to age <3 years at the time of diagnosis (date of surgical resection/biopsy)
- Participant with presumed newly diagnosed tumor in the supratentorial compartment
- Patient must have measurable disease based on RAPNO criteria
- >84 days since surgery (resection or biopsy)
- Available tumor tissue for central review

... and 39 more (see full listing online)

Exclusion (11)

- Previous exposure to cytotoxic chemotherapy or radiotherapy
- Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history
- History of recent (3 months) symptomatic congestive heart failure
- Known active, uncontrolled infection (bacterial, fungal, or viral)
- Receiving enzyme inducing antiepileptic drugs (EIAEDs)

... and 6 more (see full listing online)

Locations (2 total)

St. Jude Children's Research Hospital, Memphis, Tennessee, United States
King Hussein Cancer Center, Amman, Jordan